Combined photodynamic therapy and intravitreal ranibizumab as primary treatment for choroidal neovascularization associated with age-related macular degeneration in an Indian patient

Rishi, Pukhraj; Sen, Pratik Ranjan; Shroff, Daraius; Chhablani, Jay

doi:10.4103/0301-4738.42430

Cited by 3 publications

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Publications by Indian based authors on anti-VEGF agents started in the year 2007, with 69 peer reviewed papers published until September 2013. [ 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 ] The years between 2007-10, being populated largely by case reports and occasional case series detailing the use of anti-VEGF agents in treating CNVM of other etiology, and retinopathy of prematurity[ 41 ] (2007), AMD[ 3 ] and adjunct to trabeculectomy[ 44 ] (2008). We can see a trend towards randomized case-control studies comparing different anti-VEGF agents, the use of combination treatments in AMD and other diseases si...…”

Section: Resultsmentioning

confidence: 99%

Changing paradigms of anti-VEGF in the Indian scenario

Shanmugam

2014

Indian J Ophthalmol

View full text Add to dashboard Cite

Anti-vascular endothelial growth factors (VEGF) agents have revolutionized the treatment of retinal diseases. Use of anti-VEGF agents in the Indian Scenario present some unique challenges considering the absence of compounding pharmacies, poor penetrance of health insurance and limited affordability of the citizens of a developing economy. To study the changing paradigms of anti-VEGF use in the Indian scenario, all articles published by Indian authors, data from web-based surveys amongst Indian vitreo-retinal specialists were reviewed. In the paucity of compounding pharmacies in India, fractionation and injection techniques differ from those of developed countries. Frequent anti-VEGF monotherapy offers the best anatomical and visual results, but economics of scale do not allow the same in the Indian scenario, resulting in PRN dosing and combination of anti-VEGF with laser photocoagulation, being the commonly employed treatment protocols.

show abstract

Section: Resultsmentioning

confidence: 99%

Changing paradigms of anti-VEGF in the Indian scenario

Shanmugam

2014

Indian J Ophthalmol

View full text Add to dashboard Cite

show abstract

Future Perspectives: Agents on the Horizon

Maya

Sadiq

Agarwal

et al. 2015

Developments in Ophthalmology

View full text Add to dashboard Cite

As demonstrated in the previous chapters of this textbook, retinal pharmacotherapeutics is a rapidly developing area. The enormous burden of disease in an aging population will hopefully be met by significant improvements in our understanding and treatment of disease processes such as age-related macular degeneration (AMD) and diabetic retinopathy. This chapter will provide perspectives on select anti-angiogenic drugs currently in development, as well as therapies directed against the complement cascade for the treatment of AMD, and an anti-inflammatory monoclonal antibody for the treatment of diabetic macular edema, among others, that have not been discussed elsewhere in this book. The mechanism of action of a number of drugs under discussion differs enough to have the potential to control neovascularization in several different ways, potentially allowing for more effective management of this process with fewer treatments.

show abstract